Given the strong inhibitory effect conferred by MT1-MMP inhibition on the cell entry of SARS-CoV-2, MT1-MMP can serve as a potential therapeutic target for the treatment of COVID-19 by controlling the release of solACE2. Here, MMP14 is linked to COVID-19.